Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2009

Open Access 01-12-2009 | Review

The role of glucose lowering agents on restenosis after percutaneous coronary intervention in patients with diabetes mellitus

Authors: Chris PH Lexis, Braim M Rahel, Joan G Meeder, Felix Zijlstra, Iwan CC van der Horst

Published in: Cardiovascular Diabetology | Issue 1/2009

Login to get access

Abstract

Introduction

The prevalence of diabetes is increasing rapidly, and individuals with diabetes are at high risk for cardiovascular disorders. Subsequently the percentage of patients with diabetes subjected to revascularisation, i.e. either percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) also rises rapidly. The outcome of patients with diabetes after PCI is worse than for patients without diabetes. Restenosis is the main limiting factor of the long-term success of PCI. Although stents and antithrombotics improved outcome after PCI in both diabetics and non-diabetics, diabetics still have a worse prognosis. This leads to the suggestion that the restenosis mechanism in diabetics might be different from that in non-diabetics.

Conclusion

Several glucose lowering agents have been shown to influence the restenosis process and thus the outcome after PCI. Current data of especially metformin and thiazolidinediones indicate beneficial results as compared to insulin and sulfonylurea on restenosis. However, no large trials have been undertaken in which the effect of glucose lowering agents on restenosis is associated with improved outcome.
The purpose of this review is to summarize the effect of diabetes and glucose lowering agents on restenosis.
Appendix
Available only for authorised users
Literature
1.
2.
Huxley R, Barzi F, Woodward M: Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006, 332: 73-78.PubMedCentralCrossRefPubMed
3.
Mosseri M, Nahir M, Rozenman Y, Lotan C, Admon D, Raz I, Gotsman MS: Diffuse narrowing of coronary arteries in diabetic patients: the earliest phase of coronary artery disease. Cardiology. 1998, 89: 103-110.CrossRefPubMed
4.
Dortimer AC, Shenoy PN, Shiroff RA, Leaman DM, Babb JD, Liedtke AJ, Zelis R: Diffuse coronary artery disease in diabetic patients: fact or fiction?. Circulation. 1978, 57: 133-136.CrossRefPubMed
5.
Abaci A, Oğuzhan A, Kahraman S, Eryol NK, Unal S, Arinç H, Ergin A: Effects of diabetes mellitus on formation of coronary collateral vessels. Circulation. 1999, 99: 2239-2242.CrossRefPubMed
6.
Burke AP, Kolodgie FD, Zieske A, Fowler DR, Weber DK, Varghese PJ, Farb A, Virmani R: Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol. 2004, 24: 1266-1271.CrossRefPubMed
7.
Moreno PR, Fuster V: New Aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol. 2004, 44: 2293-2300.CrossRefPubMed
8.
Nicholls SJ, Tuzcu EM, Kalidindi S, Wolski K, Moon KW, Sipahi I, Schoenhagen P, Nissen SE: Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol. 2008, 52: 255-262.CrossRefPubMed
9.
Gruentzig A: Transluminal dilatation of coronary artery stenosis (letter). Lancet. 1978, 1: 263.CrossRef
10.
Airoldi F, Briguori C, Iakovou I, Stankovic G, Biondi-Zoccai G, Carlino M, Chieffo A, Montorfano M, Cosgrave J, Michev I, Rogacka R, Sangiorgi GM, Colombo A: Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis. Am J Cardiol. 2006, 97: 1182-1187.CrossRefPubMed
11.
Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, Fallon JT: Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation. 2000, 102: 2180-2184.CrossRefPubMed
12.
Faries PL, Rohan DI, Takahara H, Wyers MC, Contreras MA, Quist WC, King GL, Logerfo FW: Human vascular smooth muscle cells of diabetic origin exhibit increased proliferation, adhesion and migration. J Vasc Surg. 2001, 33: 601-607.CrossRefPubMed
13.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001, 285: 2486-2497.CrossRef
14.
Wegner M, Winiarska H, Bobkiewicz-Kozłowska T, Dworacka M: IL-12 serum levels in patients with type 2 diabetes treated with sulphonylureas. Cytokine. 2008, 42: 312-316.CrossRefPubMed
15.
van Werkum JW, Heestermans AA, Plokker HW, ten Berg JM: Clinical, biochemical and genetical resistance to clopidogrel in a patient with recurrent stent thrombosis. Int J Cardiol. 2007, 116: 136-137.CrossRefPubMed
16.
Walcher D, Babiak C, Poletek P, Rosenkranz S, Bach H, Betz S, Durst R, Grüb M, Hombach V, Strong J, Marx N: C-peptide induces vascular smooth muscle cell proliferation; involvement of Src-Kinase, Phosphatidylinositol 3-Kinase, and Extracellular Signal-Regulated Kinase 1/2. Circ Res. 2006, 99: 1181-1187.CrossRefPubMed
17.
Calabro P, Samudio I, Willerson JT, Yeh ET: Resistin promotes smooth muscle cell proliferation through activation of extracellular signal regulated kinase 1/2 and phosphatidfylinositol 3-kinase pathways. Circulation. 2004, 110: 3335-3340.CrossRefPubMed
18.
On YK, Park HK, Hyon MS, Jeon ES: Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients. Circ J. 2007, 71: 868-873.CrossRefPubMed
19.
Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, Heuvel van den P, Delcan J, Morel MA: A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994, 331: 489-495.CrossRefPubMed
20.
Haude M, Erbel R, Issa H, Meyer J: Quantitative analysis of elastic recoil after balloon angioplasty and after intracoronary implantation of balloon-expandable Palmaz-Schatz stents. J am Coll Cardiol. 2002, 39: 183-193.
21.
Stettler C, Alleman S, Wandel S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, De Carlo M, Erglis A, Chechi T, Ortolani P, Schalij MJ, Diem P, Meier B, Windecker S, Jüni P: Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ. 2008, 29: a1331.CrossRef
22.
Jensen LO, Maeng M, Mintz GS, Christiansen EH, Hansen KN, Galloe A, Kelbaek H, Lassen JF, Thuesen L, Thayssen P: Serial intravascular ultrasound analysis of peri-stent remodeling and proximal and distal edge effects after sirolimus-eluting or paclitaxel-eluting stent implantation in patients with diabetes mellitus. Am J Cardiol. 2009, 103: 1083-1088.CrossRefPubMed
23.
Fröbert O, Lagerqvist B, Carlsson J, Lindbäck J, Stenestrand U, James SK: Differences in restenosis rate with different drug-eluting stens in patients with and without diabetes mellitus. J Am Coll Cardiol. 2009, 53: 1660-1667.CrossRefPubMed
24.
Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Rhee KS, Chae JK, Ko JK, Park JH, Lee JH, Choi SW, Jeong JO, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Kim HS, Park SJ: A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 2-year clinical outcomes of the DES-DIABETES trial. J Am Coll Cardiol. 2009, 53: 812-813.CrossRefPubMed
25.
Schömig A, Dibra A, Windecker S, Mehilli J, Suárez de Lezo J, Kaiser C, Park SJ, Goy JJ, Lee JH, Di Lorenzo E, Wu J, Jüni P, Pfisterer ME, Meier B, Kastrati A: A meta-analysis of 16 randomized trials of sirolimus-eluting versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol. 2007, 50: 1373-1380.CrossRefPubMed
26.
The BARI investigators: The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol. 2007, 49: 1600-1606.CrossRef
27.
Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, Carrie D, Clayton TC, Danchin N, Flatcher M, Hamm CW, Hueb WA, Kähler J, Kelsy SF, King SB, Kosinki AS, Lopes N, McDonald KM, Rodriguez A, Serruys P, Sigwart U, Stables RH, Owens DK, Pocock SJ: Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet. 2009, 373: 1190-1197.CrossRefPubMed
28.
BARI 2D Study Group, Frye RL, August P, Brooks MM, Hardison RM, Kelsy SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE: A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009, 360: 2503-2515.CrossRef
29.
Serruys PW, Morice MC, Kappetein P, Colombo A, Holmes DR, Mack MJ, Ståhle E, Feldman TE, Brand van den M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW: Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009, 360: 961-972.CrossRefPubMed
30.
Tarantini G, Ramondo A, Napodano M, Favaretto E, Gardin A, Bilato C, Nesseris G, Tarzia V, Cademartiri F, Gerosa G, Iliceto S: PCI versus CABG for multivessel coronary disease in diabetics. Catheter Cardiovasc Interv. 2009, 73: 50-8.CrossRefPubMed
31.
Daemen J, Kuck KH, Macaya C, Legrand V, Vrolix M, Carrie D, Sheiban I, Suttorp MJ, Vranckx P, Rademaker T, Goedhart D, Schuijer M, Wittebols K, Macours N, Stoll HP, Serruys PW: Multivessel coronary revascularization in patients with and without diabetes mellitus. J Am Coll Cardiol. 2008, 52: 1957-1967.CrossRefPubMed
32.
Briguori C, Condorelli G, Airoldi F, Focaccio A, D'Andrea D, Cannavale M, Abarghouei AA, Giordano S, De Vivo F, Ricciardelli B, Colombo A: Comparison of coronary drug-eluting stents versus coronary artery bypass grafting in patients with diabetes mellitus. Am J Cardiol. 2007, 99: 779-784.CrossRefPubMed
33.
Lee MS, Jamal F, Kedia G, Chang G, Kapoor N, Forrester J, Czer L, Zimmer R, DeRobertis M, trento A, Makker RR: Comparison of bypass surgery with drug-eluting stents for diabetic patients with multivessel disease. Int J Cardiol. 2007, 123: 34-42.CrossRefPubMed
34.
Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, Zenni MM, Guzman LA, Bass TA, Costa MA: Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the optimizing antiplatelet therapy in diabetes mellitus (OPTIMUS) study. Circulation. 2007, 115: 1-9.CrossRef
35.
Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM: Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation. 2008, 118: 1626-1636.CrossRefPubMed
36.
Angiolillo DJ, Bernardo E, Ramirez C, Costa MA, Sabaté M, Jimenez-Quevedo P, Hernández R, Moreno R, Escaned J, Alfonso F, Banuelos C, Bass TA, Macaya C, Fernandez-Ortiz A: Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol. 2006, 48: 298-304.CrossRefPubMed
37.
Labinaz M, Madan M, O'Shea JO, Kilaru R, Chin W, Pieper K, McGuire DK, Sucedo JF, Talley JD, Lui H, Kitt MM, Califf RM, Tcheng JT: Comparison of one-year outcomes following coronary artery stenting in diabetic versus non-diabetic patients (from the enhanced suppression of the platelet IIb/IIIa receptor with integrilin therapy [ESPRIT] trial). Am J Cardiol. 2002, 90: 585-590.CrossRefPubMed
38.
Anselmino M, Ohrvik J, Malmberg K, Standl E, Rydén L: Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J. 2008, 29: 177-184.CrossRefPubMed
39.
Walker AM, Koro CE, Landon J: Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000–2007. Pharmacoepidemiol Drug Saf. 2008, 17: 760-768.CrossRefPubMed
40.
Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erquo S, Sattar N: Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009, 373: 1765-1772.CrossRefPubMed
41.
Sidhu JS, Cowan D, Kaski JC: The effects of rosiglitazone, a peroxisome proliferator-activated receptorgamma agonist, on markers of endothelial cell activation, C-reactive protein and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol. 2003, 42: 1757-1763.CrossRefPubMed
42.
Little PJ, Osman N, de Dios ST, Cemerlang N, Ballinger M, Nigro J: Anti-proliferative activity of oral anti-hyperglycemic agents on human vascular smooth muscle cells: thiazolidinediones (glitazones) have enhanced activity under high glucose conditions. Cardiovasc Diabetol. 2007, 6: 33.PubMedCentralCrossRefPubMed
43.
Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Morioka S, Akasaka T, Yoshida K: Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus. Am J Cardiol. 2002, 89: 318-322.CrossRefPubMed
44.
Choi D, Kim SK, Choi SH, Ko YG, Ahn CW, Jang Y, Lim SK, Lee HC, Cha BS: Preventive effects on rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care. 2004, 27: 2654-2660.CrossRefPubMed
45.
Nishio K, Sakurai M, Kusuyama T, Shigemitsu M, Fukui T, Kawamura K, Itoh S, Konno N, Katagiri T: A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care. 2006, 29: 101-106.CrossRefPubMed
46.
Rosmarakis ES, Falagas ME: Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials. Am Heart J. 2007, 154: 144-150.CrossRefPubMed
47.
Geng DF, Jin DM, Wu W, Wang Z, Wang JF: Effect of thiazolidinediones on in-stent restenosis in patients after coronary stenting: a meta-analysis of randomized controlled trials. Atherosclerosis. 2009, 202: 521-528.CrossRefPubMed
48.
Finn AV, Oh JS, Hendricks M, Daher M, Cagliero E, Byrne RM, Nadelson J, Crimins J, Kastrati A, Schömig A, Bruskina O, Palacios I, John MC, Gold HK: Predictive factors for in-stent late loss and coronary lesion progression in patients with type 2 diabetes mellitus randomized to rosiglitazone or placebo. Am Heart J. 2009, 157: 383-388.CrossRefPubMed
49.
Nishio K, Shigemitsu M, Kodama Y, Konno N, Katagiri T, Kobayashi Y: Comparison of bare metal stent with pioglitazone versus sirolimus-eluting stent for percutaneous coronary intervention in patients with type 2 diabetes mellitus. Cardiovasc Revasc Med. 2009, 10: 5-11.CrossRefPubMed
50.
Fang CC, Ng Yao YT, Yi-Chen , Yu CL, Chen CL, Wang SP: Angiographic and clinical outcomes of rosiglitazone in patients with type 2 diabetes mellitus after percutaneous coronary interventions: a single center experience. Angiology. 2007, 58: 523-534.CrossRefPubMed
51.
Kapinya K, Nijjar PS, Stanek M, Amanullah A: Insulin-sensitizing antihyperglycaemic medications are associated with better outcome in patients with diabetes undergoing cardiac stress testing. Intern Med J. 2008, 38: 259-264.CrossRefPubMed
52.
Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochellière R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM: Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008, 299: 1561-1573.CrossRefPubMed
53.
Clementi F, Di Luozzo M, Mango R, Luciani G, Trivisonno A, Pizzuto F, Martuscelli F, Mehta JL, Romeo F: Regression and shift in composition of coronary atherosclerotic plaques by pioglitazone: insight from an intravascular ultrasound analysis. J Cardiovasc Med. 2008, 10: 231-237.CrossRef
54.
Kao J, Tobis J, McClelland RL, Heaton MR, Davis BR, Holmes DR, Currier JW: Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol. 2004, 93: 1347-1350.CrossRefPubMed
55.
Casscells SW, Granger E, Swedorske J, Goldhammer R, Shaheen M, Dorris J, Hong A, Wiktor M: A comparison of select cardiovascular outcomes by antidiabetic prescription drug classes used to treat type 2 diabetes among Military Health System beneficiaries, fiscal year 2003–2006. Am J Ther. 2008, 15: 198-205.CrossRefPubMed
56.
Melbin LG, Malmberg K, Norhammar A, Wedel H, Rydén L: The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J. 2008, 29: 166-176.CrossRef
57.
Fisman EZ, Motro M, Tenenbaum A: Non-insulin antidiabetic therapy: current problems and future prospects. Adv Cardiol. 2008, 45: 154-170.CrossRefPubMed
58.
Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR: Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol. 1999, 33: 119-124.CrossRefPubMed
59.
Fosset M, De Weille JR, Green RD, Schmid-Antomarchi H, Lazdunski M: Antidiabetic sulphonylureas control action potential properties in heart cells via high affinity receptors that are linked to ATP-dependent K+ channels. J Biol Chem. 1988, 263: 7933-7936.PubMed
60.
Tomai F, Crea F, Gaspardone A, Versaci F, De Paulis R, Renta a Peppo A, Chiariello L, Gioffrè PA: Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation. 1994, 90: 700-705.CrossRefPubMed
61.
Huang B, Dreyer T, Heidt M, Yu JC, Philipp M, Hehrlein FW, Katz N, Al-Fakhri N: Insulin and local growth factor PDGF induce intimal hyperplasia in bypass graft culture models of saphenous vein and internal mammary artery. Eur J Cardiothorac Surg. 2002, 21: 1002-1008.CrossRefPubMed
Metadata
Title
The role of glucose lowering agents on restenosis after percutaneous coronary intervention in patients with diabetes mellitus
Authors
Chris PH Lexis
Braim M Rahel
Joan G Meeder
Felix Zijlstra
Iwan CC van der Horst
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2009
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-8-41

Other articles of this Issue 1/2009

Cardiovascular Diabetology 1/2009 Go to the issue

Original investigation

Haptoglobin genotype is a determinant of survival and cardiac remodeling after myocardial infarction in diabetic mice

Original investigation

Parathyroid hormone, but not vitamin D, is associated with the metabolic syndrome in morbidly obese women and men: a cross-sectional study

Original investigation

Biliary pancreatic diversion and laparoscopic adjustable gastric banding in morbid obesity: their long-term effects on metabolic syndrome and on cardiovascular parameters

Original investigation

The common G-866A polymorphism of the UCP2 gene and survival in diabetic patients following myocardial infarction

Original investigation

Visceral fat dominant distribution in male type 2 diabetic patients is closely related to hepatic insulin resistance, irrespective of body type

Study protocol

Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits